Srs Capital Advisors, Inc. Acadia Pharmaceuticals Inc Transaction History
Srs Capital Advisors, Inc.
- $1.5 Billion
- Q4 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 45 shares of ACAD stock, worth $897. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45
Previous 44
2.27%
Holding current value
$897
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACAD
# of Institutions
316Shares Held
164MCall Options Held
855KPut Options Held
350K-
Baker Bros. Advisors LP New York, NY42.9MShares$855 Million8.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.9MShares$278 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$241 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.71MShares$174 Million2.61% of portfolio
-
Morgan Stanley New York, NY7.3MShares$146 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.23B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...